RedHill Divests Talicia to Apotex for $18 Million
Miami, Florida, August 31, 2026 RedHill Biopharma Ltd. announced that it has entered into an agreement to divest Talicia®...
Accelerated Approval
Advertisement
IDEAYA’s IDE849 Advances Toward Phase 3 in Lung Cancer
South San Francisco, California, August 31, 2026 IDEAYA Biosciences, Inc. announced the successful completion of a U.S. Food and...
PMV Pharmaceuticals Completes PYNNACLE Ovarian Cancer Enrollment
PRINCETON, N.J., Aug. 14, 2026 PMV Pharmaceuticals, Inc. reported continued progress in its Phase 2 PYNNACLE clinical trial evaluating...
Clene Advances CNM-Au8 Toward ALS Accelerated Approval
SALT LAKE CITY, Utah, August 10, 2026 Clene Inc. announced new biomarker analyses for CNM-Au8 that will be included...
Nicox Files NCX 470 NDA in China Through Ocumension
Sophia Antipolis, France, August 10, 2026 Nicox SA announced that its exclusive Chinese licensee Ocumension Therapeutics has submitted a...
Advertisements
Innate Pharma to Advance Lacutamab Toward Phase 3 with Sobi
MARSEILLE, France, August 10, 2026 Innate Pharma SA announced plans to initiate the TELLOMAK-3 confirmatory Phase 3 study of...
FDA Approves Tudriqev for Advanced Refractory Melanoma
Silver Spring, Maryland, USA, August 8, 2026 The U.S. Food and Drug Administration (FDA) has granted accelerated approval to...
Karyopharm Eyes Accelerated FDA Approval for Selinexor
NEWTON, Mass., July 30, 2026 Karyopharm Therapeutics Inc. plans to submit a supplemental New Drug Application (sNDA) to the...
OS Therapies Advances OST-HER2 Toward FDA Approval
NEW YORK, March 31, 2026 — OS Therapies, Inc a clinical-stage oncology company specializing in listeria-based cancer immunotherapies, has...
OS Therapies Advances OST-HER2 Toward Phase 3 Trial
New York, March 27, 2026 OS Therapies has achieved a significant regulatory milestone by securing meetings with multiple global...
Advertisement
